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CD28 and the Tyrosine Kinase Lck Stimulate Mitogen-Activated
Protein Kinase Activity in T Cells via Inhibition of
the Small G Protein Rap1
KENDALL D. CAREY,1,2 TARA J. DILLON,1 JOHN M. SCHMITT,1,2 ALLISON M. BAIRD,1 AMY D. HOLDORF,3
DAVID B. STRAUS,4 ANDREY S. SHAW,3 AND PHILIP J. S. STORK1,2*
Vollum Institute1 and Department of Cell and Developmental Biology,2 Oregon Health Sciences University, Portland,
Oregon 97201; Department of Pathology and Center for Immunology, Washington University School of
Medicine, St. Louis, Missouri 631103; and Department of Medicine and Pathology,
University of Chicago, Chicago, Illinois 606374
Proliferation of T cells via activation of the T-cell receptor (TCR) requires concurrent engagement of ac-
cessory costimulatory molecules to achieve full activation. The best-studied costimulatory molecule, CD28,
achieves these effects, in part, by augmenting signals from the TCR to the mitogen-activated protein (MAP)
kinase cascade. We show here that TCR-mediated stimulation of MAP kinase extracellular-signal-regulated
kinases (ERKs) is limited by activation of the Ras antagonist Rap1. CD28 increases ERK signaling by blocking
Rap1 action. CD28 inhibits Rap1 activation because it selectively stimulates an extrinsic Rap1 GTPase activity.
The ability of CD28 to stimulate Rap1 GTPase activity was dependent on the tyrosine kinase Lck. Our results
suggest that CD28-mediated Rap1 GTPase-activating protein activation can help explain the augmentation of
ERKs during CD28 costimulation.
Maximal activation of T lymphocytes following antigen pre-
sentation is thought to require at least two signals. One signal
is generated by engagement of the T-cell receptor (TCR). A
costimulatory molecule mediates the second signal. The best-
studied costimulatory molecule is CD28, which is engaged by
antigen-presenting cells during antigen presentation. Costimu-
lation enhances production of interleukin-2 (IL-2) and T-cell
proliferation. The importance of costimulation is demonstrat-
ed by the fact that TCR engagement in the absence of costimu-
lation leads to a state of T-cell unresponsiveness termed an-
ergy.
One signaling pathway that is required for IL-2 production is
the Ras–Raf-1–extracellular-signal-regulated kinase (ERK)
pathway or the mitogen-activated protein (MAP) kinase cas-
cade (23, 34, 75) through the actions of the transcription factor
AP-1 (69). Interfering mutant Ras (2, 57), Raf-1 (34), and
MAP kinase kinase MEK (17) proteins can block IL-2 tran-
scription following CD28 costimulation. The activation of
ERK is thought to result in the activation of AP-1 (21, 74),
presumably via the transcriptional activation of c-fos through
the transcription factor Elk-1 (49). Indeed, a role for CD28 in
c-fos expression has been demonstrated (31). The MAP kinase
cascade has also been implicated in other aspects of T-cell
function (22), including the regulation of T-cell development
(10, 73).
In primary T cells, CD3 stimulation by itself can activate
ERK (54). However, ERK activation is enhanced by CD28
coengagement (52). Activation of the Ras-ERK pathway is
strongly inhibited under experimental conditions of T-cell un-
responsiveness, or anergy, induced following stimulation via
the TCR in the absence of CD28 costimulation (4, 19, 45). One
candidate effector of this blockade of Ras signaling is Rap1, a
small G protein that was initially cloned as an antagonist of
Ras-dependent transformation in fibroblasts (37). Rap1 is con-
stitutively activated in anergic T cells, and activation of Rap1
inhibits both ERK activation and IL-2 expression (4). Interest-
ingly, TCR cross-linking activates Rap1 (4, 58) while coengage-
ment of CD28 blocks this activation (58). In this study, we
examine the mechanism by which CD28 activates the ERK
signaling cascade in T cells via CD28’s inhibition of Rap1.
MATERIALS AND METHODS
Cell culture, transfections, and stimulations. The human T-cell leukemia
Jurkat cell line and JCaM1.6 T-cell isolates (stably expressing wild-type Lck and
Lck with the mutation W97A [LckW97A]) were maintained in RPMI medium
with 10% fetal calf serum (FCS) at 37°C with 5% CO2. Jurkat cells expressing the
mouse CD28 (mCD28) receptor (31) were maintained in RPMI medium–10%
FCS–50 mg of G418 per ml. For transient transfections, 5 3 107 cells were
resuspended in 400 ml of cytomix (120 mM KCl, 0.15 mM CaCl2, 10 mM
K2HPO4–KH2PO4 [pH 7.6], 25 mM HEPES [pH 7.6], 2 mM EGTA [pH 7.6], 5
mM MgCl2, 5 mM glutathione) with the appropriate cDNAs and electroporated
(250 V, 950 mF). All cDNAs were transfected at a concentration of 5 mg per 5 3
107 cells, except dominant negative Lck (dn.Lck) (10 mg), Rap1GAP1 (10 mg),
and fos-luciferase (20 mg), and the total DNA transfected held constant with the
addition of pCDNA3.1 (vector). The transfection efficiencies of transfected plas-
mids were monitored using 5 mg of cDNA encoding green fluorescent protein
(GFP; Clonetech). In all experiments, transfection efficiency was greater than
60%. After a 24-h recovery in RPMI medium with 10% FCS, cells were incu-
bated for 30 min on ice with or without anti-TCR-CD3 monoclonal antibody
(MAb) (C305 MAb 1/40 hybridoma supernatant; gift from A. Weiss, University
of California, San Francisco), anti-human CD28 MAb (CD28.2, 5 mg/ml; Pharm-
ingen, San Diego, Calif.), and/or anti-mCD28 MAb (PV-1, 5 mg/ml; gift from C.
June, Naval Medical Research Institute, Bethesda, Md.). Cells were stimulated
by addition of 10 mg of goat anti-mouse secondary antibody (Southern Biotech)
at 37°C for the indicated times. Where indicated in Fig. 1, PD98059 (50 mM) or
UO126 (20 mM) was added to cells for 30 min of pretreatment and remained in
the incubation medium for the duration of the experiment.
T-cell isolation and antibody stimulation. T cells were purified from C57BL6
splenocytes using a murine T-cell enrichment column (R&D Systems) according
to the manufacturer’s instructions. Ten million T cells were then incubated with
5 mg of anti-CD3 antibody (145-2C11; Pharmingen) with or without costimula-
tion with 10 mg of anti-CD28 antibody (37.51; Pharmingen) on ice for 30 min,
washed, and then incubated with 20 mg of goat anti-hamster immunoglobulin
(Fisher) for 5 min at 37°C and lysed for the RalGDS assay, as described below.
DNA constructs and mutant proteins. Wild-type bovine Rap1b or wild-type
human Ha-Ras (71) was tagged at the amino terminus with 23 FLAG epitope
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(Kodak) by PCR and introduced into the BamHI and XbaI sites of pcDNA3.1
vector (Invitrogen). Rap1GAP1 (RG9T; gift from P. Polakis) was N-terminally
tagged with the 23 FLAG epitope by PCR and introduced into the BamHI and
XbaI sites of pcDNA3.1. pcDNA3.FLAG-RapE63/V12 (RapE63/V12) and
dn.Rap1GAP1 were generated from pcDNA3. FLAG-RapWT and wild-type
Rap1GAP1, respectively, using a Quick-change PCR mutagenesis kit (Strat-
agene). For dn.Rap1GAP1, this resulted in the replacement of residues 284 to
286 (RKR) with LIG (59). Constitutively active and dominant negative versions
of Lck and Fyn were constructed using PCR-directed mutagenesis.
Raf-1 pull-down assays. Experiments using FLAG-tagged Rap1 (FLAG-
Rap1) and FLAG-tagged Ras (FLAG-Ras) were performed by transfecting
Jurkat cells with cDNAs encoding either FLAG-Rap1 or FLAG-Ras and by
immunoprecipitating the resulting protein complexes with anti-FLAG antibod-
ies. The proteins within the pellets were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and Raf-1 was detected by
Western blotting (71). Equal amounts of FLAG-Rap1 and FLAG-Ras were
confirmed by Western blotting.
In vitro kinase assays. For ERK and FLAG-ERK assays, treated and un-
treated cells were lysed in a buffer containing 1% NP-40, 10% sucrose, 20 mM
Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM phenyl-
methylsulfonyl fluoride, 1 mg of leupeptin per ml, 1 mM sodium orthovanadate,
and 10 mM sodium fluoride. The lysates were spun at low speed to remove
nuclei, and the supernatant was assayed for kinase activity. ERK activity was
assayed as described previously (71) using myelin basic protein (MBP) and
[g-32P]ATP as substrates and equal protein amounts per treatment condition.
For FLAG-ERK2 assays, FLAG antibodies were used to immunoprecipitate the
kinase prior to assay.
In vivo Rap and Ras activation assays. Activated Rap1 was isolated from cell
lysates using a protocol adapted from the work of Franke et al. (20). Jurkat cells
(5 3 107/ml) were stimulated with anti-TCR-CD3 and/or anti-CD28 MAb as
previously described for the times indicated in Fig. 6 at 37°C. Cells were lysed in
400 ml of ice-cold Rap lysis buffer (10% glycerol, 1% NP-40, 50 mM Tris-HCl
[pH 8.0], 200 mM NaCl, 5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1
mM leupeptin, 10 mg of soybean trypsin inhibitor per ml, 10 mM NaF, 0.5 mM
aprotinin, 1 mM Na3VO4). Lysates were clarified by centrifugation, and super-
natants containing 0.5 mg of total protein were incubated with 60 mg of the
glutathione S-transferase (GST)–RalGDS–Ras-binding domain (RBD) fusion
protein (gift of J. L. Bos, Utrecht University, Utrecht, The Netherlands) coupled
to glutathione agarose beads for 1 h at 4°C. Beads were pelleted and rinsed three
times with lysis buffer, and protein was eluted from the beads with Laemmli
buffer. Activated Ras was isolated from stimulated cell lysates using agarose-
coupled GST-Raf1-RBD provided in a Ras activation assay kit (Upstate Bio-
technology, Inc., Lake Placid, N.Y.) according to the manufacturer’s recom-
mended protocol. Proteins were separated by electrophoresis in a 12% gel,
followed by transfer to a polyvinylidine difluoride membrane. Membranes were
blocked in 5% milk and probed with either anti-Rap1 polyclonal antibody (anti-
Krev-1; Santa Cruz Biotechnology Inc., Santa Cruz, Calif.) or anti-Ras MAb
(Upstate Biotechnology, Inc.) and then with a horseradish peroxidase-conju-
gated antimouse monoclonal secondary antibody (Amersham). Proteins were
detected by enhanced chemiluminescence. Activation of ERK1 and ERK2 was
detected from 30 mg of total-cell-stimulated lysates by immunoblotting with a
phospho-specific MAP kinase MAb (New England Biolabs, Beverly, Mass.). The
densitometric analysis of the bands was performed using NIH Image software.
GAP assay. Cos7 cells were transfected with FLAG-Rap1b, FLAG-Ras,
FLAG-RapE63, or the pcDNA3.1 vector alone using Lipofectamine (GIBCO,
BRL). Cells were allowed to recover for 48 h and then lysed in Rap lysis buffer,
and FLAG epitope-tagged proteins were immunoprecipitated with 10 mg of
M2-FLAG antibody (Sigma) coupled to protein A-Sepharose for 2 h at 4°C.
Expression of FLAG-Rap and FLAG-Ras was confirmed by Western blotting.
Immune complexes retained on protein A-agarose beads were washed twice in
lysis buffer and once with Rap loading buffer (20 mM Tris [pH 7.5], 100 mM
NaCl, 1 mM MgCl2, 1 mM dithiothreitol, 5 mg of bovine serum albumin [BSA]
per ml, 5% glycerol, 0.1% NP-40, 1 mg of leupeptin per ml, 0.5 mg of aprotinin
per ml) or with Ras loading buffer (20 mM Tris [pH 7.5], 5 mM EDTA, 10 mM
NaCl, 5 mg of BSA per ml, 1 mg of leupeptin per ml, 0.5 mg of aprotinin per ml).
FLAG-Rap complexes were loaded with 0.1 mM [g-32P]GTP (3,000 Ci/mmol) at
30°C for 20 min, and FLAG-Ras complexes were loaded with 0.1 mM [g-32P]GTP
at 30°C for 10 min. The MgCl2 concentration was adjusted to 10 mM to stabilize
the FLAG-Rap-[g-32P]GTP or FLAG-Ras-[g-32P]GTP complex. Unincorpo-
rated GTP was removed by rinsing the complexes four times in ice-cold loading
buffer containing 10 mM MgCl2. Jurkat cells were stimulated as described above
and lysed in Rap lysis buffer. For each assay condition, 10 mg of total cellular
protein was added to 100 ml of exchange buffer (25 mM Tris [pH 7.5], 5 mM
MgCl2, 100 mM NaCl, 1 mM GTP, 1 mg of BSA per ml, 1 mg of leupeptin per
ml, 0.5 mg of aprotinin per ml) along with the [g-32P]GTP-loaded FLAG-Rap or
FLAG-Ras complex and incubated at 30°C for the times indicated in the legends
to Fig. 8 and 9. The reaction was stopped with 1 ml of stop buffer (20 mM Tris
[pH 7.5], 100 mM NaCl, 10 mM MgCl2). The complexes were washed four times
with 1 ml of ice-cold stop buffer to remove released 32P. Total radioactivity
remaining associated with the immune complexes was measured by scintillation
counting. [a-32P]GTP was used as a negative control for all GTPase-activating
protein (GAP) assays.
Guanine nucleotide exchange factor (GEF) assay. FLAG-Rap and FLAG-Ras
immune complexes were prepared as described above and resuspended in Rap
exchange buffer (20 mM Tris [pH 7.5], 1 mM MgCl2, 20 mM EDTA, 100 mM
NaCl, 10 mM b-mercaptoethanol, 5% glycerol, and 1 mg of BSA per ml) or Ras
exchange buffer (20 mM Tris [pH 7.5], 1 mM MgCl2, 10 mM NaCl, 5 mg of BSA
per ml, 1 mg of leupeptin per ml, 0.5 mg of aprotinin per ml). FLAG-Rap
immune complexes were loaded with 5 mCi of [3H]GDP (34 Ci/mmol) at 30°C for
20 min, and FLAG-Ras immune complexes were loaded with 5 mCi of [3H]GDP
(34 Ci/mmol) at 37°C for 10 min. FLAG-Rap-[3H]GDP or FLAG-Ras-[3H]GDP
immune complexes were stabilized by adjusting the MgCl2 concentration to 25
mM. Unincorporated [3H]GDP was removed by washing the beads four times in
loading buffer containing 25 mM MgCl2. Jurkat cells were stimulated as de-
scribed above and lysed in Rap lysis buffer. For each assay condition, 50 mg of
total cellular protein was added to 250 ml of exchange buffer containing 100 mM
GDP, 1.5 mM GTP, and 50,000 to 100,000 cpm of the FLAG-Rap-[3H]GDP or
FLAG-Ras-[3H]GDP complex and incubated at 30°C for the times indicated in
the legend to Fig. 7. The reaction was stopped by adding 1 ml of ice-cold stop
buffer (20 mM Tris [pH 7.5], 100 mM NaCl, 25 mM MgCl2), and the reaction
mixture was immediately applied to nitrocellulose filters under vacuum. The
filters were rinsed four times with 3 ml of stop buffer, and retained radioactivity
was measured by scintillation counting.
Calcium flux analyses. Calcium measurements were performed as previously
described (33). Briefly, Jurkat cells were cotransfected with (i) dn.Lck and cDNA
encoding GFP, (ii) dn.Fyn and GFP, or (iii) pcDNA3.1 (vector) and GFP as
described above. After recovery, cells were resuspended to 2 3 106/ml in com-
plete medium supplemented with a 2 mM concentration of a solution containing
the Ca21 indicator Indo-1 and 0.02% pluronic F127 (Molecular Probes, Eugene,
Oreg.) and incubated at 37°C for 30 min. Cells were then washed in ice-cold
buffer (150 mM NaCl, 1 mM CaCl2, 1 mM MgSO4, 5 mM KCl, 10 mM glycine,
15 mM HEPES [pH 7.4]), resuspended to 2 3 106 cells/ml, and then kept on ice
until use. Ca21 fluctuations, before and after the addition of anti-CD3 MAb
(Pharmingen) at 10 mg/ml, were monitored using a fluorescence-activated cell
sorter (FACS) Vantage flow cytometer by gating on the GFP-positive cells. Cells
were excited at 355 nm, and emission was measured at 480 nm, representing free
Indo-1, and at 405 nm, representing Ca21-associated Indo-1, to give a ratio of
405 nm to 480 nm.
Luciferase assays. Luciferase assays were performed as previously described
(71).
RESULTS
CD28 costimulation augments ERK activation through the
TCR and CD3. In Jurkat cells (Fig. 1A, left gel) and in primary
T cells harvested from mouse splenocytes (Fig. 1A, right gel),
activation of the TCR and CD3 by antibody cross-linking pro-
duced a modest activation of ERKs as measured by phospho-
rus-specific antibodies recognizing pT202pY204 of human
ERK1 and -2 (pERK). However, activation of ERKs was
strongly augmented upon activation of CD28 by cross-linking
antibodies (Fig. 1A). Similar results were seen for ERK activity
by in vitro kinase assay (Fig. 1B). The data demonstrate the
profound synergy between CD3 and CD28 on ERK activation
in primary T cells, as well as in Jurkat T cells. One potential
downstream target of ERKs is the expression of c-fos. Activa-
tion of the c-fos promoter coupled to luciferase (70) can also
be enhanced by CD28 costimulation. This action of CD28 on
the fos promoter was blocked by the MEK inhibitors PD98059
(14) and UO126 (15) (Fig. 1C), suggesting that the enhance-
ment of fos expression by CD3-CD28 reflected CD3-CD28’s
ability to augment ERK activity.
Rap1 limits ERK activation. It has been previously demon-
strated that CD3 engagement stimulates activation of Rap1
(58). Rap1 is a small G protein that antagonizes Ras signaling
to ERKs in a cell type-specific manner (71) through its antag-
onism of the MAP kinase kinase kinase Raf-1. In cells that
express the Raf isoform B-Raf, as in PC12 cells, Rap1 has the
opposite effect: it activates ERKs (71). In Jurkat T cells (Fig.
2A) and primary T cells (data not shown), Rap1 is expressed
but B-Raf is not. Therefore, we predict that Rap1 activation
may antagonize ERK signaling in Jurkat cells, as has been
shown for primary T cells (4, 58). Indeed, expression of the
constitutively active mutant protein of Rap1 Rap1E63 blunts
CD3-CD28 activation of ERKs (Fig. 2B). That CD3-CD28’s
activation of ERKs requires Ras was demonstrated by the
ability of the interfering mutant protein RasN17 to block ERK
activation through CD3-CD28 (Fig. 2B). To examine the role
of endogenous Rap1 to limit ERK activation following TCR-
CD3 stimulation, Rap1 activity was inhibited by transfection of
Rap1GAP1, a Rap1-specific GAP (35, 56). The inhibition of
Rap1 by Rap1GAP1 augmented CD3’s activation of ERKs
(Fig. 2C), suggesting that endogenous Rap1 serves to limit
CD3 activation of ERKs. It has been proposed that the antag-
onism of signals to ERKs by Rap1 may be due to the seques-
tration of Raf-1 by activated Rap1 (53, 61). Consistent with this
model, CD3 stimulation of Jurkat cells promoted the associa-
tion of Raf-1 and Rap1 (Fig. 2D). Interestingly, CD3 also
promoted the association of Raf-1 with Ras (Fig. 2D), consis-
tent with the ability of CD3 to activate both Rap1 and Ras
(58). This association of Ras and Raf-1 was augmented follow-
ing the inhibition of endogenous Rap1 by the Rap1 inhibitor
Rap1GAP1 (Fig. 2D), presumably because Rap1 sequesters
Raf-1 only in the GTP-loaded state (53). This finding suggests
that activation of Rap1 by CD3 limits ERK signaling by lim-
iting Ras-dependent recruitment of Raf-1.
CD28 inhibits Rap1 activation. It was previously demon-
strated that CD3’s activation of Rap1 can be inhibited by
coengagement of CD28 in phytohemagglutinin blasts and in
some T-cell lines (58). This finding was confirmed using pri-
mary splenic T cells (Fig. 3A) and the Jurkat T-cell line (Fig.
3B). This inhibition was likely a direct effect on Rap1 rather
than on an upstream activator of Rap1, as CD28 also blocked
the activation of Rap1 triggered by overexpression of C3G, a
Rap1-specific GEF (78) (Fig. 3C).
Mapping of sequences of CD28 required to inhibit Rap1
activation. To determine which residues of CD28 were re-
quired to inhibit Rap1 activation, we used Jurkat cells stably
expressing either full-length wild-type mCD28 (mCD28-WT)
or a truncated form of mCD28 lacking 16 C-terminal residues
(mCD28-CD16) (31). These cells express equivalent numbers
of mCD28 molecules, as measured by FACS analysis (data not
shown). Similar to the results with endogenous human CD28 in
Jurkat cells, engagement of mCD28 in Jurkat cells was able
to inhibit Rap1 activation by anti-CD3 antibody (Fig. 4A).
Importantly, engagement of mCD28-CD16 using anti-mCD28
antibody was unable to inhibit Rap1 activation by anti-CD3
antibody (Fig. 4A). This result demonstrates that the 16 car-
boxy-terminal residues of CD28 were required to inhibit Rap1
activation by CD3.
The 16 carboxy-terminal residues of CD28 are required for
CD28’s augmentation of ERKs but not Ras. We examined the
actions of CD3-CD28 on Ras activation using a Raf-1 fragment
containing the RBD linked to GST (GST–Raf-1–RBD). Anti-
CD3 antibody was able to stimulate Ras activity; this stimula-
tion was only slightly enhanced by the addition of antibodies to
CD28 (Fig. 4B, upper gel), similar to what occurred with
mCD28-CD16 cells (Fig. 4B, lower gel). In contrast, ERK
activation under the same conditions was strongly augmented
by CD28 (Fig. 4C, upper gel). However, CD28 costimulation of
mCD28-CD16 cells was not sufficient to activate ERKs (Fig.
4C, lower gel). This finding suggests that full ERK activation is
not solely dependent on Ras but also requires negation of the
actions of Rap1.
The tyrosine kinase Lck mediates CD28’s inhibition of
Rap1. Recently, the 16 carboxy-terminal amino acids of CD28
were shown to be important for binding and activation of Lck
(31). To directly test whether activation of Lck is involved in
inhibiting Rap1 activation, we expressed a constitutively active
form of Lck (LckF505 or ca.Lck) and analyzed its effects on
Rap1 (Fig. 5A). Expression of LckF505 was able to block the
activation of Rap1 by CD3. This was a specific effect, as ex-
pression of a constitutively active form of Fyn, a related src
family kinase (FynF531 or ca.Fyn), was unable to inhibit CD3’s
activation of Rap1 (data not shown). Indeed, overexpression of
FynF531 stimulated Rap1 activation by itself, suggesting that
the activation of Rap1 by anti-CD3 antibody might be medi-
ated via the activation of Fyn, as has been suggested (4).
Importantly, LckF505 was also able to block the activation of
Rap1 by FynF531 (Fig. 5B). These results suggest that activa-
FIG. 1. Costimulation with antibodies to CD28 augments signals to ERKs.
(A) Jurkat T cells (left gel) were stimulated with anti-TCR-CD3 antibody (a-
CD3) with or without anti-CD28 antibody (a-CD28) or left untreated, as indicat-
ed. Primary splenocytes (right gel) were stimulated with a-CD3 and/or a-CD28
as indicated, and phorbol myristate acetate (PMA) was used as a positive control.
Incubation of cells with secondary antibody alone (2° Ab) served as a negative
control. In both gels, phospho-ERK (pERK1/2) was measured using phospho-
rus-specific pERK antibodies. The positions of pERK1 and pERK2 are indi-
cated. (B) Jurkat cells were incubated with anti-TCR-CD3 antibody, anti-CD28
antibody, or PMA (50 ng/ml) for 30 min on ice or left untreated as indicated and
then stimulated at 37°C for 5 min following addition of 10 mg of a cross-linking
antibody per ml. Secondary antibody alone (2°) was used as a negative control.
Cells were lysed, and ERK2 was immunoprecipitated. Activation of immunopre-
cipitated ERK2 was measured by an in vitro kinase assay. Samples were sub-
jected to SDS-PAGE and analyzed with a PhosphorImager. A representative gel
with the position of the substrate MBP is presented. (C) Wild-type Jurkat cells
were transfected with a fragment of the c-fos promoter coupled to luciferase
(c-fos–luciferase) (70) as indicated and incubated with anti-human CD3 and
anti-human CD28 antibodies for 6 h in the absence and presence of the MEK
inhibitor PD98059 or UO126, as indicated. For all luciferase assays, lysates were
prepared and assayed for luciferase activity. The data reflect the fold activation
above basal luciferase activity (lane 1), with standard errors (n 5 3).
tion of Fyn is sufficient to activate Rap1 but that activation of
Lck blocks this activation.
We next tested whether an interfering mutant Lck (LckR273
or dn.Lck) could block CD28’s actions on Rap1. In this mutant
protein, the essential lysine at residue 273 has been replaced
with an arginine (7) to create a kinase-dead protein that has
been shown to block Lck function selectively in vivo (1, 28, 29,
41). After transfection of the Lck and Fyn genes in Jurkat cells,
we found that expression of kinase-inactive Lck, but not ex-
pression of kinase-inactive Fyn (dn.Fyn) (9), was able to com-
pletely block TCR-induced calcium flux in Jurkat T cells (Fig.
6A), suggesting that this mutant protein is selective for Lck-
FIG. 2. Rap1 limits signals from the TCR to ERKs. (A) Jurkat T cells express Rap1 but not B-Raf. Western blots for B-Raf and Rap1 expression in both PC12
cells and Jurkat cells are shown. In the left gel, low levels of Rap1 are detected in Jurkat cells compared to levels in PC12 cells. In the right gel, B-Raf expression is
very high in PC12 cells, in which Rap1 activates ERK (71), but absent in lymphocytes, in which Rap1 inhibits ERK (4). (B) Constitutively active Rap1 blocks ERK
activation by CD28 costimulation in Jurkat cells. Jurkat cells were transfected with the vector, Rap1E63, or RasN17 as indicated. Cells were treated with anti-CD3
antibody (a-CD3) and/or anti-CD28 antibody (a-CD28) for 5 min or not treated (lanes 0) as indicated. Phosphorylation of ERK1 and -2 as monitored by Western
blotting with pERK is shown. The positions of pERK1 and -2 are shown. In the lower gel, control shows equivalent levels of protein loading. (C) Jurkat cells were
transfected with 10 mg each of cDNAs encoding the vector or Rap1GAP1 as indicated. All cells received 10 mg of FLAG-ERK2 cDNA. Subsequently, cells were
incubated with anti-TCR-CD3 antibody for 30 min on ice or left untreated. Cells were then activated by incubation at 37°C for 10 min. Cells were lysed, and
FLAG-ERK2 was immunoprecipitated. Activation of immunoprecipitated ERK2 was measured by in vitro kinase assay. Samples were subjected to SDS-PAGE and
analyzed with a PhosphorImager. A representative gel with the position of the substrate MBP indicated is presented. (D) Ras activation of Raf-1 is limited by
endogenous Rap1. Jurkat cells were transfected with either FLAG-Rap1 or FLAG-Ras and treated with a-CD3 or left untreated as indicated. The associated
endogenous Raf-1 was measured following FLAG immunoprecipitation and anti-Raf-1 antibody Western blotting. For FLAG-Ras, cells were also transfected with the
vector or Rap1GAP1 as indicated. A representative gel with the position of Raf-1 indicated is shown (n 5 3).
dependent actions. Expression of dn.Lck in Jurkat cells
blocked the ability of CD28 to inhibit Rap1 activation (Fig.
6B), demonstrating that Lck mediates CD28’s regulation of
Rap1. Expression of dn.Lck in Jurkat cells also blocked the
ability of CD28 to augment ERK activation (Fig. 6C). A sim-
ilar result was found using JCaM1.6 cells that lack functional
Lck (67). In JCaM1.6 cells, stimulation through neither the
TCR nor CD28 was able to regulate Rap1 activity (Fig. 6D and
E). Interestingly, stable expression of Lck (using JCaM/LckWT
cells [11, 12]) restored Rap1 regulation by both TCR and
CD28. This result suggests that Lck is required for both Rap1
activation by CD3 and Rap downregulation by CD28. The
ability of Lck to restore Rap1 activation by CD3 may reflect
the role of Src family kinases in this process (4, 58) and, in part,
in the increased expression of Rap1 seen in Lck-expressing
cells (Fig. 6D, lower gel).
The ability of CD28 to inhibit Rap1 requires the expression
of an intact Lck SH3 domain. In addition to containing the
kinase domain (SH1 domain), Lck contains an SH2 and SH3
domain. Binding of Lck to the proline-rich domain (PRD) of
CD28 is thought to require an intact SH3 domain (31), as is
Lck-dependent activation of ERKs (11). The importance of
the SH3 domain in ERK signaling is suggested by experiments
examining the expression of a mutant Lck SH3 (LckW978A).
For example, wild-type Lck, but not LckW978A, can restore
ERK activation in Lck-defective JCaM1.6 cells (11). Using
JCaM1.6 cells expressing either wild-type Lck (JCaM/LckWT)
or LckW97A (JCaM/LckW97A), we examined whether the
SH3 domain was required in CD28’s inhibition of Rap1. Ac-
tivation of CD28 inhibited Rap1 activation in the JCaM/
LckWT cells but not in the related JCaM/LckW97A cells (Fig.
6D, upper gel, and E). These data show that CD28 inhibition
of Rap1 requires an intact SH3 domain of Lck.
CD28 inhibits Rap1 by stimulating extrinsic Rap1-specific
GTPase activity. The activity of small G proteins like Rap1 is
regulated by both positive and negative factors. GEFs activate
Rap1 by catalyzing the exchange of GDP for GTP. GAPs
negatively regulate Rap1 by enhancing the intrinsic GTPase
activity of the G protein. CD28’s inhibitory effects on Rap1
may therefore be mediated either by inhibition of Rap1 GEF
activity or by enhancement of Rap1 GAP activity.
We first examined the ability of CD28 to modulate Rap1
GEF activity. GEF activity was measured in an in vitro assay,
using recombinant Rap1 loaded with [3H]GDP, as previously
described (42, 43). While anti-CD3 antibody stimulated GEF
activity, anti-CD28 antibody had no effect on Rap1 GEF ac-
tivity. More importantly, CD28 did not inhibit the GEF activity
stimulated by anti-CD3 antibody (Fig. 7, left panel). Therefore,
inhibition of Rap1 GEF was not likely to contribute to CD28’s
inhibition of Rap1. CD28, however, did have a modest effect
on Ras exchange (right panel).
To examine the possibility that a Rap1 GAP was stimulated
by CD28, we used an in vitro GAP assay. For these experi-
ments, we used recombinant wild-type Rap1 loaded with
[g-32P]GTP and measured the release of 32P catalyzed by ex-
ogenous GAP activities. To validate this assay, we expressed
the human Rap1GAP1 protein, which displays Rap1-specific
activity (60). The specificity of Rap1GAP1 for Rap1 was shown
by its inability to hydrolyze GTP bound to Ras (Fig. 8A). In
addition, we assayed the release of [a-32P]GTP to confirm that
CD28 was not stimulating exchange under the GAP assay
conditions. Using this assay, we measured Rap1 GAP activity
from Jurkat cell lysates before and after treatment with anti-
bodies to CD3, CD28, or both (56). CD28 stimulation by itself
was able to enhance a Rap1-specific GAP activity (Fig. 8B, left
graph). Anti-CD28 antibody treatment stimulated the release
of 32P from [g-32P]GTP-loaded recombinant wild-type Rap1,
but it had no effect on [g-32P]GTP-loaded RapV12/E63, a
mutated form of Rap1 that cannot be regulated by Rap1GAP
(4) (Fig. 8A and B, right graph). CD28 did not have any effect
on Rap1 loaded with [a-32P]GTP under the conditions of this
GAP assay (Fig. 8C), consistent with the inability of CD28 to
regulate Rap1 exchange activity (Fig. 7). Consistent with this,
the Rap1 GAP activity from anti-CD28 antibody-treated cell
extracts was heat sensitive (data not shown), suggesting that
the activity in anti-CD28 antibody-treated cell extracts repre-
sented a bona fide Rap1 GAP activity. Because the activity
expressed from the transfected cDNA encoding Rap1GAP1
may be distinct from the Rap1GAP activity identified in
stimulated Jurkat T-cell lysates, we refer to the cDNA as
Rap1GAP1 and the GAP activity from the lysates as Rap1
GAP activity.
We confirmed that the last 16 residues of CD28 were re-
quired to stimulate Rap1 GTPase activity (Fig. 9A). Trunca-
tion of the last 16 residues of CD28 blocked its ability to
stimulate Rap1 GAP activity. Furthermore, expression of
LckF505 (ca.Lck) in Jurkat cells was also able to stimulate
Rap1 GTPase activity but not Ras GTPase activity (Fig. 9B).
This activation was specific because overexpression of a con-
stitutively active form of the highly related Src family kinase
(ca.Fyn) was unable to stimulate Rap1 GAP activity (Fig. 9B).
Therefore, although some Lck-dependent functions are par-
tially rescued by Fyn (12), Fyn cannot rescue Rap1 GAP acti-
vation by Lck. We next investigated the requirement of the
SH3 domain of Lck for CD28’s activation of Rap1GAP activity
using JCaM/LckWT or JCaM/LckW97A cells. As shown in Fig.
9C, JCaM/LckWT cells demonstrated elevated Rap1GAP ac-
tivity following CD28 stimulation to a significantly higher de-
gree than did JCaM/LckW97A cells. These data support a
model where CD28’s ability to stimulate Rap1 GAP activity is
mediated by the last 16 residues of CD28 and the SH3 domain
of Lck.
Mutation of the essential arginines within the catalytic active
site of all known GAPs produces an interfering mutant protein
that can block GAP function (30). We next tested the ability
of Rap1GAP1-R284L/K285I/R286G (dn.Rap1GAP1) (59) to
regulate CD28’s activation of ERK (Fig. 10). As expected,
dn.Rap1GAP1 blocked CD28’s augmentation of ERK, sug-
gesting that Rap1GAP1 (or a related Rap1-specific GAP)
played an important role in CD28’s augmentation of ERKs.
FIG. 3. Inhibition of Rap1 by CD28 costimulation in primary splenic T cells
and in human Jurkat cells. (A) Activation of Rap1 in primary splenic T cells.
Primary splenic T cells were harvested and incubated with anti-mCD3 antibody
(a-CD3) and/or anti-mCD28 antibody (a-CD28) for 5 min or left untreated as
indicated. (B) Activation of Rap1 in human Jurkat T cells. Jurkat cells were
incubated with anti-human CD3 antibody (a-CD3) and/or anti-human CD28
antibody (a-CD28) for 5 min or left untreated as indicated. (C) Inhibition of
Rap1 by CD28 following transfection of human Jurkat T cells. Wild-type Jurkat
cells were transfected with CrkL/C3G or the vector alone and incubated with
a-CD28 as indicated. In all experiments, T-cell lysates were prepared and as-
sayed for Rap1 activation using GST-RalGDS and Western blotting was per-
formed using Rap1 antiserum. The position of Rap1 in control lysates and
following isolation of glutathione-bound proteins is shown. Representative West-
ern blots are shown (n 5 3).
Rap1 assays performed in parallel confirmed that expression of
dn.Rap1GAP1 stimulated Rap1 activation (Fig. 10). Taken
together, these data show that CD3 activation of Rap1 limits
ERK signals but that CD28 activation of a Rap1 GAP aug-
ments ERK signals (Fig. 11).
DISCUSSION
The small G protein Rap1 has been proposed to be an
antagonist of Ras-dependent signaling pathways (4, 36, 62, 71)
in multiple cell types. However, two papers have also suggested
that Rap1 may not limit Ras signaling (6, 79). The data pre-
sented here show that Rap1 limits CD3 signals to ERKs in
Jurkat T cells. Moreover, we show that CD3-dependent acti-
vation of Rap1 is associated with the sequestration of Raf-1
away from Ras and propose that this provides a mechanism for
Rap1 antagonism of Ras function. Furthermore, activated
Rap1 is a target for regulation by additional intracellular sig-
FIG. 4. CD28’s inhibition of Rap 1 and enhancement of ERKs map to the 16 carboxy-terminal residues of CD28. (A) Requirement of the carboxy terminus of CD28
in the inhibition of Rap1 by CD28. Jurkat cells and Jurkat cells stably expressing wild-type mCD28 [Jurkat (mCD28-WT)] or mCD28 with its 16 carboxy-terminal amino
acids deleted [Jurkat (mCD28-CD16)] were incubated with anti-human CD3 antibody (a-hCD3) and/or anti-mCD28 antibody (a-mCD28) for 5 min or treated with
secondary antibody alone (untreated). In all experiments, T-cell lysates were prepared and assayed for Rap1 activation using GST-RalGDS and Western blotting was
performed using polyclonal Rap1 antiserum. The position of Rap1 in control lysates (A and D) and following isolation of glutathione-bound proteins is shown.
Representative Western blots are shown (n 5 3). (B) Ras activation does not require the carboxy terminus of CD28. Jurkat mCD28-WT cells and mCD28-CD16 cells
were incubated with anti-human CD3 antibody (a-CD3), anti-human CD28 antibody (a-CD28), and/or anti-mCD28 antibody (a-mCD28) for 5 min or left untreated
as indicated. Lysates were prepared and assayed for Ras activation using GST–Raf-1–RBD, and Western blotting was performed using Ras antiserum. The position
of Ras in control lysates and following isolation of glutathione-bound proteins is shown. (C) The 16 carboxy-terminal amino acids residues of CD28 that are required
for inhibiting Rap1 are required for stimulating ERK activity. Jurkat mCD28-WT cells and mCD28-CD16 cells were incubated with anti-human CD3 antibody (a-CD3),
anti-human CD28 antibody (a-CD28), and/or anti-mCD28 antibody (a-mCD28) for 5 min or left untreated as indicated. Lysates were prepared and assayed for ERK
activation using phospho-specific ERK (pERK) antibodies. Representative Western blots with the positions of pERK1 and pERK2 indicated are shown (n 5 3).
FIG. 5. Lck is sufficient to inhibit TCR stimulation of Rap1. (A) Jurkat cells
were transfected with ca.Lck or the vector alone and incubated with anti-human
CD3 antibody (a-CD3) for 2 min or left untreated as indicated. (B) Jurkat cells
were transfected with LckF505 (ca.Lck) and/or FynF531 (ca.Fyn) or the vector
alone. In both experiments, T-cell lysates were prepared and assayed for Rap1
activation using GST-RalGDS and Western blotting was performed using Rap1
antiserum. The position of Rap1 in control lysates and following isolation of
glutathione-bound proteins is shown. Representative Western blots are shown
(n 5 3).
FIG. 6. Lck is required for CD28’s inhibition of Rap1 and augmentation of ERK. (A) dn.Lck inhibits mobilization of intracellular calcium. Jurkat T cells were
transfected with the vector (black line), dn.Lck (dark-gray line), or dn.Fyn (light-gray line) and preloaded with Indo-1. Cells were then stimulated with anti-CD3 MAb
as indicated. Changes in the mobilization of intracellular free calcium, presented as ratios of 405 nm to 480 nm (representing Ca21-associated Indo-1 [405 nm] and
free Indo-1 [480 nm]), are shown as a function of time. Expression of dn.Fyn had no effect on Ca21 flux. However, expression of dn.Lck blocked Ca21 in these cells.
(Inset) Successful loading of Jurkat cells, expressing dn.Lck, with Indo-1 was confirmed by treating cells with anti-CD3 MAb and ionomycin (1 iono), which resulted
in a Ca21 flux, or treating them with anti-CD3 antibody alone (2 iono), which resulted in a block in Ca21 flux. Results of a representative experiment are shown (n 5
3). (B) Jurkat cells were transfected with LckR273 (dn.Lck) or the vector alone and incubated with anti-human CD3 antibody (a-CD3) and/or anti-human CD28
antibody (a-CD28) for 2 min or left untreated as indicated. T-cell lysates were prepared and assayed for Rap1 activation using GST-RalGDS, and Western blotting
was performed using Rap1 antiserum. The position of Rap1 in control lysates and following isolation of glutathione-bound proteins is shown. Representative Western
blots are shown (n 5 3). (C) Jurkat cells were transfected with dn.lck or the vector along with FLAG-ERK2 and treated with antibodies to CD3 and/or CD28 for 5
min as indicated. The phosphorylation of FLAG-ERK2 was monitored by pERK Western blotting. The position of pFlag-ERK2 is shown. A representative Western
blot is shown (n 5 3). (D) JCaM1.6 cells stably expressing the vector (JCaM/vector), wild-type Lck (JCaM/LckWT) or LckW97A (JCaM/LckW97A) were incubated
with anti-human CD3 antibody and/or anti-human CD28 antibody for 5 min or left untreated as indicated. Cell lysates were prepared and assayed for Rap1 activation
using GST-RalGDS, and Western blotting was performed using Rap1 antiserum (upper blot). A representative western blot with the position of Rap1 is shown following
a GST-RalGDS pull-down assay (n 5 3). The lower Western blot shows the relative levels of expression of Rap1 in these cell lines. (E) The data in panel D are
presented as the averages of results of three independent experiments with standard errors. Untr., untreated cells.
nals. In particular, inhibition of Rap1 via CD28 costimulation
enhances ERK activation. Therefore, Rap1 is a negative reg-
ulator of the ERK signaling pathway in T cells and its inhibi-
tion by CD28 augments signals to ERK.
We show here that Lck is both necessary and sufficient for
CD28’s inhibition of Rap1 and its enhancement of ERKs. A
structure-function analysis of CD28 revealed that the last 16
residues of the CD28 cytoplasmic domain were required for
these effects. Contained within these residues is a PRD capable
of associating with the SH3 domain of Lck (31). Therefore, we
tested whether constitutively active forms of Lck could also
affect Rap1 activation. Constitutively, activation of Lck strong-
ly inhibited Rap1 activation by TCR engagement. Further-
more, interfering with endogenous Lck function blocked both
CD28’s inhibition of Rap1 and augmentation of ERKs.
Lck activation by CD28 is mediated by interactions between
Lck’s SH3 domain and the PRD of CD28 (31). Interestingly,
the SH3 domain of Lck has previously been shown to be
important for Lck’s activation of ERK (11) but not for other
actions of Lck, including the activation and phosphorylation of
ZAP-70 and LAT (66). Here, we show that Lck is also required
for the ability of CD28 to inhibit Rap1 activation, suggesting
that CD28’s ability to enhance ERK activation is mediated by
its ability to inhibit Rap1. Our data demonstrate that both the
SH3 domain of Lck and the PRD of CD28 are required for
this action. Since the activation of Rap1 is negatively regu-
lated by Rap1-specific GAPs, Rap1 GAPs are potential tar-
gets of CD28 action. Indeed, measurements of Rap1 GAP
activity in cell extracts after CD28 engagement revealed that
CD28 engagement does result in significant stimulation of
Rap1 GAP activity and that this stimulation requires both
an intact PRD of CD28 and the SH3 domain of Lck.
Despite extensive research into its mechanism of action, the
exact function of CD28 remains unclear. Most current models
propose that CD28 provides an essential second signal re-
quired for T-cell activation. In these models, T-cell activation
requires two distinct signals for full activation (27, 40). The first
signal is transduced by the TCR, while CD28 provides the
second signal, a process termed costimulation (48). However,
the exact signal mediated by CD28 engagement has remained
elusive. While it has been proposed that CD28 regulates sig-
nals like that activating jun N-terminal protein kinase (JNK)
or NF-kB, these signals require coengagement of the TCR;
CD28 engagement by itself does not activate JNK or NF-kB
(68). Furthermore, JNK activation utilizes the membrane-
proximal region of CD28, a region that is dispensable for IL-2
production (3).
Recently, it was shown that CD28 engagement by itself can
induce tyrosine phosphorylation as well as stimulate a c-fos
FIG. 7. Lack of regulation of Rap1 GEF activity by CD28. Jurkat cells were
incubated with anti-human CD3 antibody (a-CD3) and/or anti-human CD28
antibody (a-CD28) for 5 min or left untreated (Untr.) as indicated. Lysates were
prepared and incubated for 10 min at 30°C with recombinant [3H]GDP-loaded
Rap1 protein (left panel) or Ras protein (right panel) bound to agarose beads.
The percentages of [3H]GDP released from the beads are indicated. Standard
errors are shown (n 5 3).
FIG. 8. Enhancement of Rap1 GTPase activity by CD28. (A) Specificity of Rap1GAP1 for Ras and selected Rap1 mutants in vitro. Human Rap1GAP1 was
expressed in Cos7 cells and incubated with recombinant Rap1 mutant proteins loaded with [g-32P]GTP. The percentages of hydrolysis of [g-32P]GTP from wild-type
Rap1(Rap1 WT), RapV12/E63 (V12/E63), Ras, and buffer alone are indicated by the percentage of g-32P released from Rap or Ras loaded in vitro. (B) CD28
stimulation of Rap1 GAP activity and introduction of E63 into RapV12, which blocks GTPase activity. Jurkat cells were incubated with anti-human CD3 antibody
(a-CD3) and/or anti-human CD28 antibody (a-CD28) for 5 min or left untreated (Untr.) as indicated. Lysates were prepared and incubated for 20 min with
recombinant FLAG-tagged Rap1 (left graph) or RapV12/E63 (right graph) loaded in vitro with [g-32P]GTP, as indicated. The percentages of release of [g-32P]GTP
are shown with standard errors. (n 5 3). (C) Cells were treated as described for panel B and were assayed with [g-32P]GTP. Release of a-32P was monitored as described
in Materials and Methods, and the percentages of release of [g-32P]GTPase is shown with standard errors (n 5 6).
receptor construct in an Lck-dependent fashion (31). This find-
ing suggested that CD28 may not transduce a distinct signal but
that rather it functions to potentiate signals initiated by the
TCR. In this model, although both TCR and CD28 can couple
to Lck, CD28 also utilizes Lck in a distinct way to further
augment TCR signaling (16, 64). It has been proposed that Lck
function is dictated not only through its activation but also by
association with specific receptors. Here we extend those find-
ings and demonstrate that Lck activation by CD28 results in
the generation of a specific signal, activation of a Rap1 GAP,
which is distinct from Lck’s other functions, which are thought
to be triggered by binding proteins associated with the TCR
(63, 66). The findings presented here can potentially reconcile
these two models and provide new insight into the function of
CD28 costimulation.
In the absence of signaling by the TCR, CD28 is still capable
of activating Lck, resulting in Rap1 GAP activation. However,
in the absence of Rap1 activation, the stimulation of a Rap1
GAP is without effect on ERK signaling. This can explain why
little to no signaling had previously been detected by CD28
engagement itself. In contrast, in the presence of Rap1 activa-
tion, CD28 engagement may have a significant effect. Consis-
tent with previous reports, we found that TCR engagement is
a potent activator of Rap1 (4, 58). Because Rap1 opposes the
action of Ras, this suggests that the magnitude of signals trans-
duced by the TCR is self-limiting in the absence of CD28.
Thus, in the presence of activated Rap1, the stimulation of a
Rap1 GAP may have a powerfully synergistic effect (Fig. 11),
allowing ERK signaling to reach its maximal potential. This
provides a model by which coengagement of CD28 with the
TCR can have such a profound effect on T-cell activation.
Rap1 activation is a mechanism utilized by multiple cells,
including both T and B cells, to modulate signals downstream
of Ras (4, 25, 26, 50, 62, 71). The ability of Rap1 to antagonize
Ras-dependent actions requires Rap1 activation. This antago-
nism of signaling pathways to ERK contrasts with the actions
of Rap1 in other cell types that express the Raf-1 isoform
B-Raf, a positive effector of Rap1 (62, 71). Neither peripheral
lymphocytes nor Jurkat cells express B-Raf, and Rap1 antag-
onism of Raf-1 appears to be its major action in these cells.
Rap1 activation is triggered by a growing family of Rap1-
specific GEFs that can be activated by a diverse set of intra-
cellular-signaling pathways (13, 24, 50, 78). This activation of
Rap1 may account for the ability of multiple intracellular sig-
nals like that of cyclic AMP (cAMP) to inhibit Ras-dependent
pathways in lymphocytes (32, 46, 47), as well as other cell types
(5, 8, 77). cAMP can potently activate Rap1 in multiple cell
types (71, 72), including lymphocytes (data not shown) (72),
and the hydrolysis of cAMP via CD28-regulated phosphodies-
terases has recently been proposed as a mechanism for CD28
costimulation (44).
Here, we identify Rap1 GAPs as novel targets of CD28
signaling. Dysregulation of Rap1 GAPs may underscore some
of the signaling defects seen in states of T-cell hyporesponsive-
ness, such as anergy (4). Although largely unexplored, the
recent identification of a growing family of Rap1-specific
GAPs demonstrates that they are widely expressed in multiple
cells types, including T cells (38, 51). Some have a ubiquitous
pattern of expression, while other Rap1 GAPs are restricted in
FIG. 9. Involvement of Lck in CD28’s enhancement of Rap1 GTPase activity. (A) The 16 carboxy-terminal amino acid residues of CD28 are required for stimulating
Rap1GAP activity. Jurkat cells stably expressing full-length wild-type mCD28 (mCD28-WT) or Jurkat cells stably expressing mCD28-CD16 were treated with anti-human CD3
antibody (a-hCD3) and/or anti-mCD28 antibody (a-mCD28) or left untreated (Untr.) as indicated, and GTPase assays were performed as described in Materials and Methods.
Percentages of release of [g-32P]GTP are shown with standard errors (n 5 3). (B) Lck, but not Fyn, stimulates Rap1GAP activity. Jurkat cells were transfected with the vector
alone, ca.Lck, or ca.Fyn and incubated with recombinant [g-32P]GTP-loaded Rap1 (left) and either the vector alone or ca.Lck and incubated with recombinant [g-32P]GTP-
loaded Ras (right) as indicated. Percentages of release of [g-32P]GTP are shown with standard errors (n 5 5). (C) JCaM/vector, JCaM/LckWT, or JCaM/LckW97A
cells were incubated with anti-human CD3 antibody (a-CD3) and/or anti-human CD28 antibody (a-CD28) for 5 min or left untreated as indicated. Cell lysates were
prepared and assayed for Rap1 GAP activity as described for panel B. Percentages of release of [g-32P]GTP are shown with standard errors (n 5 3).
FIG. 10. Interfering with Rap1 GAP blocks CD28 enhancement of ERKs.
Jurkat cells were transfected with FLAG-ERK2 along with the vector and
dn.Rap1GAP1 or the vector alone as indicated. Cells were treated with anti-CD3
antibody (a-CD3) and/or anti-CD28 antibody (a-CD28) or left untreated (lanes
0), as indicated. In the upper blot, the activation of FLAG-ERK2 was monitored
using FLAG immunoprecipitation followed by pERK Western blotting. The po-
sition of pFlag-ERK2 is shown. A representative gel is shown (n 5 4). In the low-
er blot, lysates prepared as described above were subjected to a GST-RalGDS
pull-down assay and Rap1 Western blotting. The position of Rap1 is shown.
their pattern of expression (60, 76). For example, the Rap1
GAP SPA-1 appears to be expressed predominantly in lym-
phocytes (38). The structural diversity of these Rap1 GAPs
suggest that they will have multiple mechanisms of regulation.
At present, the mechanism of Rap1 GAP regulation is not well
known (55); however, roles for heterotrimeric G proteins have
been suggested (35, 51). Our results using dn.Rap1GAP1 sug-
gest that this protein (or a related GAP) may be the target of
CD28’s actions in Jurkat cells. Because CD28’s ability to reg-
ulate both Rap1 and ERKs is common to both Jurkat and
primary T cells, it is possible that regulation of Rap1GAP
activity represents an important mechanism for modulating
ERK activation in vivo as well.
The activation of Rap1 may play an important role in reg-
ulating signals transduced by the TCR. Rap1, which is acti-
vated by engagement of the TCR alone, is likely to set a
threshold level for ERK activation that prevents activation of
T cells by nonspecific ligands. This is important because it can
potentially explain how the TCR achieves its exquisite sensi-
tivity and specificity (39, 65). Although it is generally assumed
that inhibitory signals function to terminate signaling pro-
cesses, inhibitory molecules can also play important roles in
shaping the character of the signaling response. Activation of
inhibitory molecules during the signaling process can suppress
weak signals, ensuring that nonspecific ligands are unable to
activate the T cell. The CD28-Lck signaling pathway allows the
T cell a unique mechanism for amplifying signals that over-
come a specific threshold. CD28 and Lck not only reverse the
Rap1 signal but may also stimulate the Ras pathway on their
own. This process allows signaling by the TCR to achieve a
switch-like character (18); i.e., all signals below a specific
threshold are suppressed, and all signals above a specific
threshold are amplified to their maximal potential. The re-
quirement of a second molecule, CD28, to relieve the inhibi-
tion allows the T cell a second layer of temporal control and
may help to explain the function of CD28 in T-cell costimula-
tion. It can also help to explain the persistent activation of
Rap1 in anergic cells (4).
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